Hermann Bihler

Hermann Bihler

Auto-generated profile, based on publicly available information

Hermann Bihler

CFFT Lab, Cystic Fibrosis Foundation, Lexington, MA, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Nature
Verified
Journal Article
Closed access
PDF file
DMDaniel T. Montoro
Daniel T. Montoro
AHAdam L. Haber
Adam L. Haber
MBMoshe Biton
Moshe Biton
VVVladimir Vinarsky
Vladimir Vinarsky
Brian LinBrian Lin
Brian Lin
JRJayaraj Rajagopal
Jayaraj Rajagopal

16 June 2016 in Cell Stem Cell
Verified
Journal Article
Open access
PDF file
HMHongmei Mou
Hongmei Mou
VVVladimir Vinarsky
Vladimir Vinarsky
PTPurushothama Rao Tata
Purushothama Rao Tata
KBKarissa Brazauskas
Karissa Brazauskas
SCSoon Choi
Soon Choi
JRJayaraj Rajagopal
Jayaraj Rajagopal
Functional modeling of many adult epithelia is limited by the difficulty in maintaining relevant stem cell populations in culture. Here, we show that dual inhibition of SMAD signaling pathways enables robust expansion of primary epithelial basal cell populations. We find that TGFβ/BMP/SMAD pathway signaling is strongly activated in luminal and suprabasal cells of several epithelia, but suppressed in p63+ basal cells. In airway epithelium, SMAD signaling promotes differentiation, and its inhibition leads to stem cell hyperplasia. Using dual SMAD signaling inhibition in a feeder-free culture system, we have been able to expand airway basal stem cells from multiple species. Expanded cells can produce functional airway epithelium physiologically responsive to clinically relevant drugs, such as CFTR modulators. This approach is effective for the clonal expansion of single human cells and for basal cell populations from epithelial tissues from all three germ layers and therefore may be broadly applicable for modeling of epithelia.

1 January 2019 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
JCJohn Paul Clancy
John Paul Clancy
CCCalvin U. Cotton
Calvin U. Cotton
SDScott H. Donaldson
Scott H. Donaldson
GSGeorge M. Solomon
George M. Solomon
DVDonald R. VanDevanter
Donald R. VanDevanter
KTKatherine L. Tuggle
Katherine L. Tuggle
New drugs that improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein with discreet disease-causing variants have been successfully developed for cystic fibrosis (CF) patients. Preclinical model systems have played a critical role in this process, and have the potential to inform researchers and CF healthcare providers regarding the nature of defects in rare CFTR variants, and to potentially support use of modulator therapies in new populations. The Cystic Fibrosis Foundation (CFF) assembled a workshop of international experts to discuss the use of preclinical model systems to examine the nature of CF-causing variants in CFTR and the role of in vitro CFTR modulator testing to inform in vivo modulator use. The theme of the workshop was centered on CFTR theratyping, a term that encompasses the use of CFTR modulators to define defects in CFTR in vitro, with application to both common and rare CFTR variants. Several preclinical model systems were identified in various stages of maturity, ranging from the expression of CFTR variant cDNA in stable cell lines to examination of cells derived from CF patients, including the gastrointestinal tract, the respiratory tree, and the blood. Common themes included the ongoing need for standardization, validation, and defining the predictive capacity of data derived from model systems to estimate clinical outcomes from modulator-treated CF patients. CFTR modulator theratyping is a novel and rapidly evolving field that has the potential to identify rare CFTR variants that are responsive to approved drugs or drugs in development.

1 July 2019 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
HVHillary C. Valley
Hillary C. Valley
KBKatherine M. Bukis
Katherine M. Bukis
ABAlisa Bell
Alisa Bell
YCYi Cheng
Yi Cheng
EWEric Wong
Eric Wong
MMMartin Mense
Martin Mense

15 January 2003 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
ABAdam Bertl
Adam Bertl
Jose-Manuel Ramos-RinconJose-Manuel Ramos-Rincon
Jose-Manuel Ramos-Rincon
JLJost Ludwig
Jost Ludwig
HLHella Lichtenberg‐Fraté
Hella Lichtenberg‐Fraté
JRJohn Reid
John Reid
PLPer O Ljungdahl
Per O Ljungdahl
Summary: Saccharomyces cerevisiae cells express three defined potassium‐specific transport systems en‐coded by TRK1 , TRK2 and TOK1 . To gain a more complete understanding of the physiological function of these transport proteins, we have constructed a set of isogenic yeast strains carrying all combinations of trk1 Δ, trk2 Δ and tok1 Δ null mutations. The in vivo K + transport characteristics of each strain have been documented using growth‐based assays, and the in vitro biochemical and electrophysiological properties associated with K + transport have been determined. As has been reported previously, Trk1p and Trk2p facilitate high‐affinity potassium uptake and appear to be functionally redundant under a wide range of environmental conditions. In the absence of TRK1 and TRK2 , strains lack the ability specifically to take up K + , and trk1 Δ trk2 Δ double mutant cells depend upon poorly understood non‐specific cation uptake mechanisms for growth. Under conditions that impair the activity of the non‐specific uptake system, termed NSC1, we have found that the presence of functional Tok1p renders cells sensitive to Cs + . Based on this finding, we have established a growth‐based assay that monitors the in vivo activity of Tok1p.

16 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJyoti Sharma
Jyoti Sharma
MDMing Du
Ming Du
EWEric Wong
Eric Wong
VMVenkateshwar Mutyam
Venkateshwar Mutyam
YLYao Li
Yao Li
DBDavid Michael Bedwell
David Michael Bedwell
Premature termination codons (PTCs) prevent translation of a full-length protein and trigger nonsense-mediated mRNA decay (NMD). Nonsense suppression (also termed readthrough) therapy restores protein function by selectively suppressing translation termination at PTCs. Poor efficacy of current readthrough agents prompted us to search for better compounds. An NMD-sensitive NanoLuc readthrough reporter was used to screen 771,345 compounds. Among the 180 compounds identified with readthrough activity, SRI-37240 and its more potent derivative SRI-41315, induce a prolonged pause at stop codons and suppress PTCs associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity. Combining readthrough agents that target distinct components of the translation machinery is a promising treatment strategy for diseases caused by PTCs.